BARRON BRUCE N 4
4 · CORTEX PHARMACEUTICALS INC/DE/ · Filed Sep 19, 2012
Insider Transaction Report
Form 4
ORIGIN VENTURES II LP
10% Owner
Transactions
- Other
Common Stock
2012-08-10+24,200,507→ 24,200,507 total(indirect: See Footnote)
Footnotes (2)
- [F1]Received in exchange for 645,556 shares of Pier Pharmaceuticals, Inc. Series A Preferred Stock, a Convertible Promissory Note in the aggregate principal amount of $400,000 and accrued interest thereon, and a stock option to purchase 20,000 shares of Common Stock of Pier Pharmaceuticals, Inc., all in connection with the merger among Cortex Pharmaceuticals, Inc., Pier Pharmaceuticals, Inc. and Pier Acquisition Corp. (the "Merger"). On the effective date of the Merger, the closing price of the Common Stock of Cortex Pharmaceuticals, Inc. was $0.06 per share.
- [F2]Shares are held of record by Origin Ventures II, L.P. ("OVII"). Origin Ventures II Management, LLC ("OVIIM") is the general partner of OVII. Bruce N. Barron and Steven N. Miller are managing directors of OVIIM and exercise shared voting and investment power with respect to the shares owned by OVII. Each of the reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein.